Paris (France), April 14, 2023 – 5:35 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinicalstage biotechnology company specializing in the development of innovative drugs targeting tumor DNA
Damage Response (DDR) and driver oncogenes, today announced new date for the publication of its 2022
full-year results.

The publication of the 2022 full-year results is postponed to April 21, 2023, after market close.